An interventional study of nursing educational consultation in Stroke and Patient Education, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Stroke by University Hospital, Bordeaux — 9 open to participants now, 10 under way, 2 of them phase 3. Stroke · University Hospital, Bordeaux.
Among the 27 studies in Stroke by University Hospital, Bordeaux, this one is the 5th largest by planned enrollment of the 22 interventional ones that give a count, is the only one that started in 2026, is one of 17 with no phase, and was the 27th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →9 of the 27 studies in Stroke by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Bordeaux · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18–80
University Hospital, Bordeaux · Sites in France
Ages 18–75
University Hospital, Bordeaux · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18–80
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 166 across the 22 interventional studies, 1,138 across the 5 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Bordeaux is the lead sponsor of 807 studies on the registry; 198 are open to participants now.
5 of the studies in Stroke by University Hospital, Bordeaux that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03998852Phase 3University Hospital, BordeauxIn Vivo Involvement of the Cholinergic and Dopaminergic Systems in the Pathophysiology of Apathy. | 2027-04-13 |
| NCT06059144Phase 3University Hospital, BordeauxInduced Hypertension in Acute PRogrESsive Perforating Artery Stroke Using Peripheral Dilute noREpinephrine | 2027-08-28 |
| NCT06837311University Hospital, BordeauxPost-Stroke Secondary Prevention With Digital Monitoring | 2027-03-25 |
| NCT04796714University Hospital, BordeauxAntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE | 2027-05-03 |
| NCT05306834University Hospital, BordeauxStopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 27 studies in Stroke by University Hospital, Bordeaux, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This prospective, single-center, randomized study will evaluate the impact of implementing an educational nursing consultation at the end of hospitalisation for stroke patients returning home on overall adherence to stroke-related medication during the 4-month follow-up visit.
Stroke is the leading cause of acquired disability in adults and represents a public health problem in terms of frequency, severity, and cost.
In France, the prevalence of stroke is estimated at 1.6%, with about 150,000 new cases each year. The risk of recurrence after a stroke remains high, nearly 6% at 1 year and 13% at 5 years. Some strokes and their recurrences are preventable through targeted prevention, particularly addressing cardiovascular risk factors.
The care pathway for a patient suffering from a stroke or TIA in a medical service includes:
In the stroke care pathway, therapeutic education is an integral part of secondary prevention. It is an essential complement to the management of patients following a stroke and should be initiated as early as possible after the acute phase, hence during the stay in the neurological intensive care unit. However, ETP programs are scarce within general hospitals. Of about twenty programs listed in Nouvelle Aquitaine, only a quarter are accessible in general hospitals. The implementation of a nursing educational consultation, at the end of the acute management of the stroke, will allow for conveying the key messages of secondary prevention.
The investigators of this research propose to study the impact of this nursing educational consultation on the patient's adherence to their post-stroke care plan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The patients will benefit from the usual care provided by the unit, specifically adapted for patients being discharged home following a stroke.
The patients benefits from an additionnal nursing educational consultation at the end of hospitalization.
Other: nursing educational consultation
At the end of hospitalization, the patient will receive a nursing education consultation prior to discharge. This consultation will provide personalized information regarding stroke pathology, its mechanisms and etiology, medication treatments, personal vascular risk factors, and the implementation of the care plan (rehabilitation, additional examinations). Discharge documents are provided at the end of this consultation.
Measurement of the proportion of patients with high adherence to their prescribed medications after stroke, upon returning home
The adherence will be evaluate using the 8-item Morisky Medication Adherence Scale (MMAS-8), in both arms. The MMAS-8 will provide an overall assessment of all treatments prescribed in the context of stroke. This score is an 8-item self-administered questionnaire, validated in French, intended for adults, which allows patients to be classified into three groups according to their score: * High adherence: score = 8 * Moderate adherence: score from 6 to \<8 * Low adherence: score \< 6 For the primary analysis, adherence will be considered as a binary outcome: high adherence versus moderate or low adherence.
Time frame: 4 months
Description of the specfic therapeutic adherence
Description of medication adherence by therapeutic class compared with prescriptions at hospital discharge, in both groups, based on patient self-report.
Time frame: 4 & 12 months
Evaluation of Patient adherence to the post-stroke care plan (1)
Evaluation of the proportion of patients attending the post-stroke follow-up consultation in both groups.
Time frame: 4 & 12 months
Evaluation of Patient adherence to the post-stroke care plan (2)
Evaluation of the proportion of rehabilitation interventions completed (physiotherapy and/or speech therapy), calculated relative to what was prescribed at hospital discharge (number of completed prescriptions per patient / number of prescribed rehabilitation interventions), in both groups, based on patient self-report.
Time frame: 4 & 12 months
Evaluation of Patient adherence to the post-stroke care plan (3)
Evaluation of the proportion of prescribed post-stroke complementary investigations completed, calculated relative to what was prescribed at hospital discharge (number of completed tests / number of prescribed tests), in both groups based on patient self-report.
Time frame: 4 & 12 months
Evaluation of Patient adherence to the post-stroke care plan (4)
Comparison of mean composite scores for overall adherence to the post-stroke care plan between the two groups : This composite score (range: 0-3), developed for this study, defines three adherence categories: * High adherence: score ≥ 2 * Moderate adherence: score ≥ 1.5 to \< 2 * Low adherence: score \< 1.5
Time frame: 4 & 12 months
Assessment of the patient's knowledge about stroke
Comparison of mean scores on the "My Stroke Knowledge" questionnaire between the two groups. This score assesses patient knowledge of essential stroke-related information. It was inspired by the Stroke Knowledge Score used in a study by Benoit C. conducted at Foch Hospital. A 2-item self-administered questionnaire \[Appendix 2\] was developed to assess: * Knowledge of main stroke warning signs (5 points) * Appropriate response in case of symptom onset (2 points) These two components will be analyzed separately, and changes in mean scores will be compared between groups. A score ≥5 (including the full 2 points for appropriate response) indicates very good stroke knowledge.
Time frame: 4 & 12 months
Evaluation of secondary prevention and vascular risk factors (1)
Proportion of patients with blood pressure within the target range: * Either ≤135mmHg/85mmHg based on the average of home blood pressure self-measurements * Or ≤140mmHg/90mmHg based on blood pressure measurements taken during consultations in both groups
Time frame: 4 & 12 months
Evaluation of secondary prevention and vascular risk factors (2)
Proportion of patients who achieved the target reduction of 1 mmol/L in LDL in both groups and description of the differences between the level measured at discharge and the levels measured during follow-up visits (in mmol/L), in both groups .
Time frame: 4 & 12 months
Evaluation of secondary prevention and vascular risk factors (3)
Proportion of patients diagnosed with diabetes via fasting blood glucose measurement in both groups Measure unit : g/l
Time frame: 4 & 12 months
Evaluation of secondary prevention and vascular risk factors (4)
Among diabetic patients: proportion of patients who achieved the personalised HbA1c target, in both groups Creatinine levels will be monitored as a simple follow-up, without a specific target to be achieved Measure unit : g/l
Time frame: 4 & 12 months
Evaluation of secondary prevention and vascular risk factors (5)
Proportion of patients who have completely stopped smoking (self-reported), in both groups
Time frame: 4 & 12 months
Evaluation of secondary prevention and vascular risk factors (6)
Mean difference in body mass index (BMI) between the two groups weight and height will be combined to report BMI in kg/m\^2).
Time frame: 4 & 12 months
Evaluation of post-stroke disability (1)
Comparison of mean Stroke-Specific Quality of Life (SS-QOL) scores between groups. This patient-reported outcome assesses health-related quality of life specific to stroke. Patients respond based on the previous week. The total score (49-245) includes multiple domains (energy, family roles, language, mobility, mood, etc.). Each domain will be assessed at each visit and its evolution analyzed. Higher scores indicate better functioning .
Time frame: 4 & 12 months
Evaluation of post-stroke disability (2)
Comparison of mean Hospital Anxiety and Depression Scale (HADS) scores between groups. This validated instrument (French version available) screens for anxiety and depressive symptoms in post-stroke patients. It includes 14 items (scored 0-3): * 7 for anxiety * 7 for depression Scores ≥8 indicate possible symptoms, and ≥11 indicate definite symptoms. Scores will be assessed at each visit and their evolution analyzed
Time frame: 4 & 12 months
Evaluation of post-stroke disability (3)
Comparison of mean modified Rankin Scale (mRS) scores between groups. This scale (0-6) assesses disability and its impact on daily activities and return to normal life. Its evolution will be analyzed. A validated French structured interview version will be used
Time frame: 4 & 12 months
Evaluation of post-stroke disability (4)
Comparison of mean National Institutes of Health Stroke Scale (NIHSS) scores between groups. This scale (0-40) evaluates neurological deficit severity and is widely used in neurovascular practice. Lower scores indicate fewer neurological sequelae. Scores will be assessed at each visit and their evolution analyzed.
Time frame: 4 & 12 months
Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 24 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 24 months is close to that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →